Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis

被引:124
作者
Hayama, Satoshi
Daigo, Yataro
Kato, Tatsuya
Ishikawa, Nobuhisa
Yamabuki, Takumi
Miyamoto, Masaki
Ito, Tomoo
Tsuchiya, Eiju
Kondo, Satoshi
Nakamura, Yusuke
机构
[1] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan
[2] Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido 060, Japan
[3] Hokkaido Univ, Grad Sch Med, Dept Surg Pathol, Sapporo, Hokkaido 060, Japan
[4] Kanagawa Canc Ctr, Res Inst, Kanagawa, Japan
关键词
CELL LUNG-CANCER; AURORA-KINASE INHIBITORS; EXPRESSION PROFILES; CHROMOSOME SEGREGATION; THERAPEUTIC TARGET; ANTICANCER DRUGS; GENE-EXPRESSION; CDNA MICROARRAY; BREAST-CANCER; KINETOCHORE;
D O I
10.1158/0008-5472.CAN-06-2137
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We found cotransactivation of cell division associated 1 (CDCA1) and kinetochore associated 2 (KNTC2), members of the evolutionarily conserved centromere protein complex, in non-small cell lung carcinomas (NSCLC). Immunobistochemical analysis using lung cancer tissue microarray confirmed high levels of CDCA1 and KNTC2 proteins in the great majority of lung cancers of various histologic types. Their elevated expressions were associated with poorer prognosis of NSCLC patients. Knockdown of either CDCA1 or KNTC2 expression with small interfering RNA significantly suppressed growth of NSCLC cells. Furthermore, inhibition of their binding by a cell-permeable peptide carrying the CDCA1-derived 19-amino-acid peptide (11R-CDCA1(398-416)) that correspond to the binding domain to KNTC2 effectively suppressed growth of NSCLC cells. As our data imply that human CDCA1 and KNTC2 seem to fall in the category of cancer-testis antigens, and that their simultaneous up-regulation is a frequent and important feature of cell growth/survival of lung cancer, selective suppression of CDCA1 or KNTC2 activity and/or inhibition of the CDCA1-KNTC2 complex formation could be a promising therapeutic target for treatment of lung cancers.
引用
收藏
页码:10339 / 10348
页数:10
相关论文
共 41 条
[31]  
OGAWA E, 2006, P NATL ACAD SCI USA, V103, P7036
[32]   Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray [J].
Saito-Hisaminato, A ;
Katagiri, T ;
Kakiuchi, S ;
Nakamura, T ;
Tsunoda, T ;
Nakamura, Y .
DNA RESEARCH, 2002, 9 (02) :35-45
[33]   Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].
Schiller, JH ;
Harrington, D ;
Belani, CP ;
Langer, C ;
Sandler, A ;
Krook, J ;
Zhu, JM ;
Johnson, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :92-98
[34]  
Sozzi G, 2001, EUR J CANCER, V37, pS63
[35]   Protection of NIT-1 pancreatic beta-cells from immune attack by inhibition of NF-kappa B [J].
Stephens, LA ;
Thomas, HE ;
Kay, TWH .
JOURNAL OF AUTOIMMUNITY, 1997, 10 (03) :293-298
[36]   ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway [J].
Suzuki, C ;
Daigo, Y ;
Ishikawa, N ;
Kato, T ;
Hayama, S ;
Ito, T ;
Tsuchiya, E ;
Nakamura, Y .
CANCER RESEARCH, 2005, 65 (24) :11314-11325
[37]  
Suzuki C, 2003, CANCER RES, V63, P7038
[38]  
Taniwaki M, 2006, INT J ONCOL, V29, P567
[39]   Drug Target Discovery by Gene Expression Analysis: Cell Cycle Genes [J].
Walker, M. G. .
CURRENT CANCER DRUG TARGETS, 2001, 1 (01) :73-83
[40]   Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death [J].
Weaver, BAA ;
Cleveland, DW .
CANCER CELL, 2005, 8 (01) :7-12